Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 6/20 | 0.88 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.95 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | AGXT | P21549 | 2/20 | 0.57 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4634 | 0.98 | TAAR1 (1.00) | TAAR1MAOBIDO1AGXTAOC3 | |
| Bromide SCHEMBL25228226 | 0.95 | TAAR1 (0.95) | TAAR1MAOBIDO1AGXTAOC3 | |
| SCHEMBL9468301 | 0.95 | TAAR1 (0.95) | TAAR1MAOBIDO1AGXTAOC3 | |
| Iodide SCHEMBL29184237 | 0.95 | TAAR1 (0.95) | TAAR1MAOBIDO1AGXTAOC3 | |
| SCHEMBL4842037 | 0.91 | MAOB (1.00) | TAAR1MAOBAOC3CYP1A2CYP2A6 | |
| SCHEMBL9468421 | 0.91 | TAAR1 (0.88) | TAAR1MAOBIDO1AGXTAOC3 | |
| Phenethylamine SCHEMBL22129843 | 0.90 | TAAR1 (0.84) | TAAR1MAOBCYP2A6 | |
| Tyramine SCHEMBL8339170 | 0.88 | TAAR1 (0.81) | TAAR1MAOBIDO1AGXTALDH1A1 | |
| Hydrochloric Acid SCHEMBL1029559 | 0.87 | TAAR1 (0.73) | TAAR1MAOBIDO1AGXTAOC3 | |
| SCHEMBL4463419 | 0.86 | TAAR1 (0.78) | TAAR1MAOBIDO1AOC3CALM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116193878-A | Amine halide salt doped carbon-based perovskite solar cell | 河北工业大学 | 2023-05-30 | — | — | CN | claimed |
| CN-115988889-A | Perovskite solar cell treated by ammonium chloride salt and preparation method thereof | 河北工业大学 | 2023-04-18 | — | — | CN | claimed |
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC | 2005-06-09 | — | — | US | claimed |
| CN-117903115-A | Sulfone-substituted heterocyclic structure compound, preparation method thereof and application thereof in medicine | 上海致根医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-116193878-A | Amine halide salt doped carbon-based perovskite solar cell | 河北工业大学 | 2023-05-30 | — | — | CN | disclosed |
| CN-115988889-A | Perovskite solar cell treated by ammonium chloride salt and preparation method thereof | 河北工业大学 | 2023-04-18 | — | — | CN | disclosed |
| CN-106536503-B | A kind of tyrosine kinase inhibitor and application thereof | 北京澳合药物研究院有限公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-110114346-A | Improved process for the preparation of R-6-hydroxy-8- [ 1-hydroxy-2- [2- (4-methoxyphenyl) -1, 1-dimethylethylaminoethyl ] -2H-1, 4-benzoxazin-3 (4H) -one hydrochloride | INKE股份公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-106536503-A | Tyrosine kinase inhibitor and uses thereof | 山东轩竹医药科技有限公司 | 2017-03-22 | — | — | CN | disclosed |
| CN-103965108-B | A kind of method of synthesizing Laudanine | ANTI-DRUG INFORMATION TECHNOLOGY CENTER OF THE MINISTRY OF PUBLIC SECURITY (CN) | 2015-09-23 | — | — | CN | disclosed |
| CN-104447544-A | Preparation and application of mono-benzylisoquinoline alkaloid derivative having pancrelipase inhabitation activity | UNIV CHINA PHARMA | 2015-03-25 | — | — | CN | disclosed |
| CN-100363331-C | Method for preparing p-hydroxy phenylethylamine hydrochloride | JIANGSU TECH TEACHER S COLLEGE (CN) | 2008-01-23 | — | — | CN | disclosed |
| EP-1644343-B1 | 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | EP | disclosed |
| CN-1915965-A | Method for preparing p-hydroxy phenylethylamine hydrochloride | JIANGSU TECH TEACHER S COLLEGE (CN) | 2007-02-21 | — | — | CN | disclosed |
| US-20060154928-A1 | Novel 2,4-diamino-1,3,5-triazine derivative | HAMARI CHEMICALS, LTD. (JP) | 2006-07-13 | — | — | US | disclosed |
| EP-1574503-A1 | NOVEL 2,4-DIAMINO-1,3,5-TRIAZINE DERIVATIVE | Hamari Chemicals Co., Ltd. (JP) | 2005-09-14 | — | — | EP | disclosed |
| EP-0901459-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997037967-A1 | CALCILYTIC COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 1997-10-16 | — | — | WO | disclosed |
| US-4493931-A | REACTING PHOSPHORAMIDE WITH ALDEHYDE, THEN A BASE, HEATING, HYDROLYSIS, REDUCTION, AND ACID TREATMENT | SANOFI (FR) | 1985-01-15 | — | — | US | disclosed |
| EP-0017376-A1 | Phenylacetamide compounds and an analgesic composition containing them | KISSEI PHARMACEUTICAL CO. LTD (JP) | 1980-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124607-A1 | 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1B, ADRB2 | MAOB 169/4885TAAR1 96/4885IDO1 1736/4885 |
| US-20060154928-A1 | Novel 2,4-diamino-1,3,5-triazine derivative | DAZAP1, DCUN1D5, TLR5 | MAOB 1850/4885TAAR1 732/4885IDO1 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.